Recombinant PCSK9 (Bococizumab Biosimilar) 抗体
Research Grade
适用: 人
ELISA
宿主: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原 See all PCSK9 (Bococizumab Biosimilar) products
- PCSK9 (Bococizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
-
Mammalian Cells
- Expression System
- Mammalian cells
-
克隆类型
- 单克隆
-
标记
- This PCSK9 (Bococizumab Biosimilar) antibody is un-conjugated
- 应用范围
- ELISA
- 原理
- Bococizumab Biosimilar - Anti-PCSK9, NARC1, PC9 mAb
- 产品特性
- Antibody Type: IgG2-kappa
- 纯化方法
- Recombinant antibody expressed in mammalien cells and purified.
- 质量等级
- Research Grade
- 亚型
- IgG2
-
-
- 限制
- 仅限研究用
-
- 缓冲液
- PBS pH 7.5
- 储存条件
- -80 °C
- 储存方法
- store at -80°C
-
- 抗原
- PCSK9 (Bococizumab Biosimilar)
- Abstract
- PCSK9 (Bococizumab Biosimilar) 产品
- 物质类
- Biosimilar
- 背景
-
PF-04950615,RN-316
Bococizumab is a monoclonal antibody that was development by Pfizer targeting proprotein convertase subtilisin kexin type 9 (PCSK9). Bococizumab has been investigated for the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia. - CAS-编号
- 1407495-02-6
-
You are here:
